What pricing strategy is specifically designed for 'orphan drugs' that treat rare diseases affecting fewer than 200,000 patients in the US?

The pharmaceutical industry uses various pricing strategies, especially for specialized medications. 'Orphan drugs' treat rare diseases affecting small patient populations, creating unique pricing challenges and strategies. This trivia tests your knowledge about how these critical but niche medications are priced in the marketplace and the economic factors that influence their development and accessibility.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Value-based pricing with government subsidies and extended patent protection to recoup R&D costs from a small patient population
Loss-leader pricing where manufacturers sell orphan drugs at a loss to gain market share for their more profitable mainstream medications
Penetration pricing with initially low costs that gradually increase as patient dependency develops and treatment continues
Bundle pricing where orphan drugs are only sold in combination with more common medications to distribute development costs